Massimo Tempestilli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8668785/publications.pdf

Version: 2024-02-01

643344 591227 42 813 15 citations h-index papers

g-index 43 43 43 1831 docs citations times ranked citing authors all docs

27

#	Article	lF	CITATIONS
1	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 135-142.	0.6	O
2	Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects. Journal of Antimicrobial Chemotherapy, 2022, 77, 2683-2687.	1.3	3
3	Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis. European Journal of Clinical Pharmacology, 2021, 77, 1583-1585.	0.8	3
4	Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. Journal of Antimicrobial Chemotherapy, 2021, 76, 3320-3322.	1.3	3
5	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. Nutrients, 2021, 13, 3571.	1.7	2
6	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death and Disease, 2020, 11, 921.	2.7	96
7	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. Journal of Antimicrobial Chemotherapy, 2020, 75, 2977-2980.	1.3	90
8	Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment. Aids, 2019, 33, 493-502.	1.0	6
9	Cerebrospinal fluid abacavir concentrations in <scp>HIV</scp> â€positive patients following onceâ€daily administration. British Journal of Clinical Pharmacology, 2018, 84, 1380-1383.	1.1	4
10	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. Journal of Antimicrobial Chemotherapy, 2018, 73, 160-164.	1.3	2
11	Altered Brain Cholesterol/Isoprenoid Metabolism in a Rat Model of Autism Spectrum Disorders. Neuroscience, 2018, 372, 27-37.	1.1	48
12	Development and validation of an HPLCâ€UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIVâ€positive patients. Biomedical Chromatography, 2018, 32, e4274.	0.8	8
13	UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 183-190.	1.2	34
14	Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment. AIDS Research and Human Retroviruses, 2018, 34, 907-908.	0.5	5
15	Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 621-623.	0.7	3
16	Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. Gastroenterology Insights, 2015, 7, 5822.	0.7	11
17	Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1967-73.	1.4	14
18	Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. PLoS ONE, 2015, 10, e0123772.	1.1	67

#	Article	IF	CITATIONS
19	Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir. Hepatology, 2014, 60, 1109-1110.	3.6	11
20	Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. Journal of Antimicrobial Chemotherapy, 2014, 69, 1760-1766.	1.3	7
21	Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. BMC Medical Genetics, 2014, 15, 76.	2.1	20
22	Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. Journal of the International AIDS Society, 2014, 17, 19589.	1.2	6
23	Determination of telaprevir in plasma of HCVâ€infected patients by HPLCâ€UV. IUBMB Life, 2013, 65, 800-805.	1.5	7
24	Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors. International Immunopharmacology, 2013, 16, 492-497.	1.7	12
25	Low Plasma Concentrations of Albumin Influence the Affinity Column–Mediated Immunoassay Method for the Measurement of Tacrolimus in Blood During the Early Period After Liver Transplantation. Therapeutic Drug Monitoring, 2013, 35, 96-100.	1.0	12
26	Antiretroviral Therapeutic Drug Monitoring in HIV-Infected Pregnant Women: Maternal Immunovirological Outcome at Delivery and During the 18 Month Follow-Up Period. Current HIV Research, 2012, 10, 606-613.	0.2	3
27	Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors. Current HIV Research, 2012, 10, 162-164.	0.2	22
28	Stable Virologic Suppression during Raltegravir plus Atazanavir Dual-Therapy Taken Every other Day: A Case Report. Journal of AIDS & Clinical Research, 2012, 01, .	0.5	0
29	Whole blood levels evaluation measuring tacrolimus by ACMIA method on washed erythrocytes in a liver transplant recipient with circulating heterophilic antibodies. Clinica Chimica Acta, 2011, 412, 1480-1481.	0.5	5
30	Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart. Antiviral Therapy, 2011, 16, 797-803.	0.6	9
31	Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. Malaria Journal, 2011, 10, 141.	0.8	15
32	Multicompartment vectors as novel drug delivery systems: selective activation of $T^{\hat{1}\hat{2}\hat{1}'}$ lymphocytes after zoledronic acid delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 153-161.	1.7	28
33	Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. Aids, 2010, 24, 1083-1084.	1.0	20
34	A rare case of severe myopathy associated with etravirine use. Aids, 2010, 24, 1088-1090.	1.0	6
35	Determination of antituberculosis drug concentration in human plasma by MALDIâ€TOF/TOF. IUBMB Life, 2010, 62, 387-393.	1.5	11
36	Use of novel antiretroviral agents in rescue regimens: A case of early virological failure to raltegravir. Scandinavian Journal of Infectious Diseases, 2010, 42, 237-239.	1.5	1

#	Article	IF	CITATION
37	Transplacental Transfer of Antiretroviral Drugs and Newborn Birth Weight in HIV-Infected Pregnant Women. Current HIV Research, 2009, 7, 620-625.	0.2	32
38	CD3ζ Downâ€Modulation May Explain Vγ9Vδ2 T Lymphocyte Anergy in HIVâ€Infected Patients. Journal of Infectious Diseases, 2009, 199, 432-436.	1.9	8
39	Simultaneous determination of maraviroc and raltegravir in human plasma by HPLCâ€UV. IUBMB Life, 2009, 61, 470-475.	1.5	23
40	Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating $\hat{V}^39\hat{V}^2$ T cells. Aids, 2009, 23, 555-565.	1.0	55
41	Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza. Emerging Infectious Diseases, 2008, 14, 121-128.	2.0	81
42	Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection. Journal of Hepatology, 2006, 44, 475-483.	1.8	20